Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes
- PMID: 3487380
- PMCID: PMC11038568
- DOI: 10.1007/BF00199122
Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes
Abstract
The antitumor potency and specificity of syngeneic immune peritoneal exudate cells were tested. Groups of DBA/2 mice were immunized against syngeneic SL2 tumor cells. Then 6 days after the last immunization the antitumor potency, and the specificity of the immunization reaction was tested by injecting groups of the immunized mice with 10(3) to 5 X 10(7) DBA/2 derived L1210, L5178Y, P815 or SL2 tumor cells, and injecting immune peritoneal exudate cells into DBA/2 mice which had been injected 2 h earlier i.p. with 2 X 10(4) or 2 X 10(5) L1210, L5178Y, P815, or SL2 cells. Furthermore the tumor specific cytotoxicity in vitro of isolated immune (vs SL2) peritoneal macrophages was tested against L1210, L5178Y, P815, and SL2 cells. The "reciprocal" experiments (previous immunization against L1210, L5178Y, or P815 cells and 'challenge' with SL2) were also done. Finally, we tested the tumor-specific cytotoxicity of isolated immune peritoneal T-lymphocytes. It was shown that the rejection of tumor cells in previously immunized mice, the antitumor efficacy of the transferred immune peritoneal exudate cells and the in vitro cytotoxicity of purified immune peritoneal macrophages and lymphocytes, were tumor-specific reactions. That is only between the SL2 and L5178Y tumors were cross-reactions observed. However, this cross-reaction was not found at the level of cytotoxic T-cells. This suggests that cytotoxic T-cells and cytotoxic macrophages probably have different mechanisms of recognition of the specific tumor target cells. Treatment of macrophage monolayers, prepared from macrophages of immunized mice, with monoclonal anti-Thy-1 antibodies plus complement caused no decrease in cytotoxicity. This shows that macrophages can really express specific cytotoxicity. Tumoricidal macrophages probably obtain their tumor specificity through the activities of tumor-specific factors produced by sensitized T-cells.
Similar articles
-
The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.Cancer Immunol Immunother. 1986;23(2):113-8. doi: 10.1007/BF00199816. Cancer Immunol Immunother. 1986. PMID: 3536093 Free PMC article.
-
Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.Immunobiology. 1992 Nov;186(3-4):214-29. doi: 10.1016/S0171-2985(11)80251-2. Immunobiology. 1992. PMID: 1490728
-
Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice.Cancer Immunol Immunother. 1987;24(1):25-36. doi: 10.1007/BF00199829. Cancer Immunol Immunother. 1987. PMID: 3493070 Free PMC article.
-
Murine macrophage cytotoxicity induced by mastocytoma cells, cell-free mastocytoma exudates, and extracts.Immunopharmacology. 1981 Sep;3(3):241-51. doi: 10.1016/0162-3109(81)90006-0. Immunopharmacology. 1981. PMID: 6796544
-
Eradication of tumor cells after injection into immunized hosts compared with the eradication of tumor cells after transfer of immune peritoneal exudates into tumor-bearing recipients.Cancer Immunol Immunother. 1983;16(2):72-6. doi: 10.1007/BF00199234. Cancer Immunol Immunother. 1983. PMID: 6559103 Free PMC article.
Cited by
-
Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.Cancer Immunol Immunother. 1989;28(2):123-30. doi: 10.1007/BF00199112. Cancer Immunol Immunother. 1989. PMID: 2783887 Free PMC article.
-
Cyclophosphamide modifies the induction kinetics but not cell types and cytotoxic mechanisms of antitumor cells elicited with OK-432 plus attenuated tumor cells.Cancer Immunol Immunother. 1991;34(3):143-9. doi: 10.1007/BF01742304. Cancer Immunol Immunother. 1991. PMID: 1756530 Free PMC article.
-
Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells.Cancer Immunol Immunother. 1992;34(4):233-40. doi: 10.1007/BF01741791. Cancer Immunol Immunother. 1992. PMID: 1537056 Free PMC article.
-
Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.Cancer Immunol Immunother. 1989;30(1):28-33. doi: 10.1007/BF01665027. Cancer Immunol Immunother. 1989. PMID: 2598173 Free PMC article.
-
The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.Cancer Immunol Immunother. 1986;23(2):113-8. doi: 10.1007/BF00199816. Cancer Immunol Immunother. 1986. PMID: 3536093 Free PMC article.
References
-
- Biondi A, Roach JA, Schlossman SF, Todd RF. Phenotypic characterization of human T-lymphocyte populations producing macrophage-activating factor (MAF) lymphokines. J Immunol. 1984;133:281. - PubMed
-
- Chapes SK, Haskill S. Role of Corynebacterium parvum in the activation of peritoneal macrophages. II. Identification of distinguisable antitumor activities by macrophage subpopulations. Cell Immunol. 1983;76:49. - PubMed
-
- De Boer RJ, Hogeweg P, Dullens HFJ, De Weger RA, Den Otter W. T-lymphocyte interactions in the anti-tumor response: A mathematical model. J Immunol. 1985;134:2748. - PubMed
-
- Den Otter W, Dullens HFJ. Transfer of macrophages and antitumor resistance. In: Herscowitz HB, Holden HT, Bellanti JA, Ghaffar A, editors. Manual of macrophage methodology. New York: Marcel Dekker Inc; 1981. p. 501.
MeSH terms
LinkOut - more resources
Full Text Sources